MeSH tree: D27.505.519.389.739
Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts cancer cells' ability to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 ...
Aug 5, 2026
0
57
Significant advances have been made in the development of patient-derived tumor "organoids" for preclinical research in two new studies led by Weill Cornell Medicine investigators. Organoids are three-dimensional clumps of ...
Jul 20, 2026
0
4
Researchers at the Mount Sinai Tisch Cancer Center have identified a previously underrecognized folate deficiency that may cause severe anemia in some patients receiving PARP inhibitors, a widely used class of targeted cancer ...
Jul 6, 2026
0
4
Lung cancer remains the leading cause of cancer-related deaths worldwide and is generally thought to arise from mutations acquired over a lifetime through environmental exposures. However, clinicians are increasingly encountering ...
Jun 30, 2026
0
3
A research team from the Germans Trias i Pujol Research Institute (IGTP) has developed a new experimental model based on induced pluripotent stem cells (iPSCs) that makes it possible to reproduce in the laboratory the progression ...
Jun 22, 2026
0
6
What if a new combination of cancer drugs could sound an alarm, alerting the body's immune system to invoke a targeted response to cancer cells? Findings from a new study appear in a paper published in Nucleic Acids Research.
Jun 11, 2026
0
7
A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumor types. The study, which is a Phase I/II ...
May 22, 2026
0
5
A study led by Dr. Jason Pitt, Principal Investigator at the Cancer Science Institute of Singapore (CSI Singapore), has identified eight new "signatures" of DNA patterns (gains and/or losses) in breast cancer. By analyzing ...
May 18, 2026
0
6
Researchers at The University of Texas MD Anderson Cancer Center have identified a key enzyme—RNase H2—that helps triple-negative breast cancer (TNBC) cells survive high levels of DNA replication stress. Because many breast ...
May 4, 2026
0
13
Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern ...
May 4, 2026
0
7
